Aquestive Therapeutics (AQST) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed Aquestive Therapeutics (AQST) over the past year, losing 14.8% versus a loss of 28.6%. Over five years, MNPR leads with a +242.1% price change compared with +23.0% for AQST. Aquestive Therapeutics is the larger company by market cap ($599.9 million vs $530.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | MNPR |
|---|---|---|
| Share price | $4.78 | $78.96 |
| Market cap | $599.95M | $529.99M |
| 1-day change | +0.42% | -5.98% |
| YTD return | -26.01% | +28.61% |
| 1-year return | -28.55% | -14.80% |
| 5-year return | +23.00% | +242.08% |
| EPS (TTM) | $-0.66 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $124.82 |
| 52-week low | $2.93 | $50.07 |
| Distance from 52-week high | -36.69% | -36.74% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +95.19% | +64.54% |
| Average volume | 2.68M | 213.15K |
| Shares outstanding | 125.51M | 6.71M |
| Employees | 147 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed AQST by 13.7 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
AQST vs MNPR FAQ
Which is bigger, Aquestive Therapeutics or Monopar Therapeutics?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $599.95M compared with $529.99M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, AQST or MNPR?
MNPR returned -14.80% over the past 12 months, compared with -28.55% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.